Release date: 2014-12-15 Illumina announced that the HiSeq X Ten sequencing system will return in January, and the early application of the technology will take some time, but GEN predicts the six major applications that Illumina X Ten may achieve in 2015. Illumina X Ten's sequencing capabilities are very powerful. One machine can complete 18,000 human genome sequencing a year. Although large-scale genome sequencing will face a series of challenges, it is now possible to put these concerns on hold and think about the scientists can use it. What interesting work does the technology accomplish? Here are the six major applications of GEN prediction. 1 Neonatal and pediatric disease prediction The neonatal intensive care unit and the children's hospital treat a large number of children with serious diseases every year, and many of these deadly diseases have their genetic basis. Some of these are known genetic diseases that can be diagnosed by clinical genetic testing. However, there are still a large number of diseases that cannot be detected by genetic testing, but seriously affect children's health. There are many pilot programs, such as NIH's “undiagnosed disease planâ€, which is performed by exon sequencing. Exon sequencing can reveal 25-30% of pathological mutations on average. However, whole-genome sequencing can identify difficult-to-capture exon regions and can also detect structural variations. With the application of X Ten system, whole genome sequencing is just the first step in the work to be done below. It operates faster and does not require a hybrid reaction, ranging from single nucleotide variation to large fragment loss. Patients, their parents, and even siblings can perform whole-genome sequencing if feasible. 2. Drug trials and pharmacogenomics A great prospect for genetic research is the realization of individualized medicine: the treatment of diseases specific to each individual's genetic makeup. Achieving individualized medicine requires individual genetic differences in disease prognosis and drug response. Many drug genome programs are currently underway, and many use SNP analysis and targeted sequencing technologies. Whole-genome sequencing can better facilitate these efforts because whole-genome sequencing captures a wider range of variations. Whole-genome sequencing can also be applied to the forefront of clinical trials, which can divide patients into responses into a number of groups. 3. Control variation and expression of quantitative trait loci (eQTLs) An important expense of the International Human Genome HapMap Project is the identification of genetic variants from fibroblast lines, led by Coriell. After obtaining all SNP genotypes, the researchers can analyze gene expression, initially through chip analysis, and later through RNA-seq technology, which ultimately links these results to variation. These analyses yielded tens of thousands of expressed quantitative trait loci (eQTLs) that can be analyzed to understand how genetic variation affects transcription. Imagine how powerful data can be obtained by analyzing the same sample using the most advanced RNA-Seq and WGS (whole genome sequencing) techniques (RNA-seq is done on other platforms, such as Hiseq2000, because X Ten can only Perform genome-wide sequencing). The ENCODE Project Consortium and several other teams have revealed the way in which transcription is widespread, and there is no doubt that these conclusions cannot be reached using only past SNP chip analysis. 4. Rare tumor research Work such as the Cancer Genome Atlas (TCGA) and the International Cancer Genome Project (ICGC) identified somatic mutations in a number of cancer types. Most of the work is done by exon sequencing and whole genome sequencing, and in view of cost considerations, mainly exon sequencing. Nonetheless, these efforts are extremely effective in revealing recurring variations and pathways. However, these efforts are mainly based on those common tumor types. However, with the popularity of whole-genome sequencing, rare tumor types can be studied by the same means. By using samples from TCGA, ICGC, and other databases as reference pairs, we can obtain somatic variation data for many rare tumors. This can not only help patients with rare tumors, but also help to understand the specificity of biology. Whole genome sequencing is an extremely effective tool for studying these rare tumors. Based on our little knowledge of these tumors, all the mutations can be captured by whole genome sequencing, and the variation of single nucleotide sites can be known in one sequencing. Large enough to rearrange chromosomes. The large-scale application of whole-genome sequencing in cancer research is a matter of course. 5. Familial disease genomics research This may seem similar to the first application (newborn and pediatric disease prediction), but it is another study that requires the discovery of multi-lineage causes affected by familial genetic diseases. Familial studies and case-control studies may be a bit outdated, but the current research method is back to the researcher's line of sight. One of the most important reasons is to study variation within a family with different alleles, rather than Research is conducted between unrelated individuals. However, genome-wide sequencing is more costly than case studies. In a genealogy, researchers can use linkage analysis, but sequencing is needed to determine the specific variation that causes the disease. At this time, the advantages of whole-genome sequencing will be reflected, which allows researchers to understand the non-coding and structural variation of the linkage region, rather than simply exploring genetic variation. This is very important, just ask a genetic researcher who will tell you that a large number of relevant peaks in the study area are not related to known genes. Such examples can be described as countless. 6. Study large-scale groups with rich phenotypes Genotypic studies are often needed for a wide range of phenotypic group samples. In the past, SNP analysis and exon sequencing were used to study. As the population participated in the study, the number of samples and phenotypes increased. At this time, large-scale, longitudinal studies of complex and diverse phenotypes are important for identifying potential genes. After the introduction of HiSeq X Ten, whole-genome sequencing is still too costly for a group of 10,000 samples, but for a pre-experiment with a sample size of 200, 500 or 1000, it is still simple and feasible, and can be found in The results that can be replicated in a large group. Researchers can select small samples with the broadest phenotypes (biomarkers, clinical data, RNA-seq, health records) and then study their associations with whole-genome sequencing. In addition to the research fields mentioned above, X Ten system can also be promising in many fields, and researchers need to continue to explore. Source: Bio Valley Pu Foam Dressing,Adhesive Foam Dressing,Gelfoam Dressing,Hydrophilic Foam Dressing Roosin Medical Co.,Ltd , https://www.roosinmedical.com
Illumina announced that the HiSeq X Ten sequencing system will return in January, and the early application of the technology will take some time, but GEN predicts the six major applications that Illumina X Ten may achieve in 2015.